Luminopia Inc

Luminopia Inc. is an FDA-cleared digital therapeutics company specializing in VR-based treatment for pediatric amblyopia (lazy eye) in children aged 4–12. The company delivers its prescription-only Luminopia software through commercially available VR headsets, enabling patients to receive binocular vision therapy while watching curated TV content instead of traditional patching. The treatment regimen requires one hour daily, six days weekly, with clinical trials demonstrating significant vision improvement within 4–12 weeks. Luminopia is prescribed by ophthalmologists, optometrists, and orthoptists; the company handles fulfillment, patient support, and compliance monitoring. Designed for at-home use alongside corrective lenses, Luminopia achieved 94% parental preference over conventional patching and demonstrated 85% median treatment completion rates, addressing the long-standing compliance challenges in amblyopia management.